Novartis Plans to Cut 1,400 Drug Sales Jobs in U.S.
This article is for subscribers only.
Novartis AG plans to cut 1,400 sales jobs in the U.S. as the drugmaker prepares for patent expirations and product introductions.
The reductions will result in a one-time cost of about $85 million, the Basel, Switzerland-based company said in a statement today. The cuts don’t affect the sales forces for cancer treatments or the Sandoz generic-drug unit, said Anna Frable, a company spokeswoman.